Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Other Non-Current Assets (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Other Non-Current Assets for 8 consecutive years, with $5.8 million as the latest value for Q1 2026.

  • For Q1 2026, Other Non-Current Assets changed 0.05% year-over-year to $5.8 million; the TTM value through Mar 2026 reached $5.8 million, changed 0.05%, while the annual FY2025 figure was $5.8 million, 197.44% up from the prior year.
  • Other Non-Current Assets hit $5.8 million in Q1 2026 for Kymera Therapeutics, roughly flat from $5.8 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $6.1 million in Q1 2023 and bottomed at $2.0 million in Q4 2024.
  • Average Other Non-Current Assets over 5 years is $4.6 million, with a median of $5.8 million recorded in 2025.
  • Year-over-year, Other Non-Current Assets skyrocketed 754.19% in 2022 and then tumbled 66.44% in 2024.
  • Kymera Therapeutics' Other Non-Current Assets stood at $6.1 million in 2022, then dropped by 5.2% to $5.8 million in 2023, then crashed by 66.44% to $2.0 million in 2024, then soared by 197.44% to $5.8 million in 2025, then grew by 0.17% to $5.8 million in 2026.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $5.8 million, $5.8 million, and $5.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.